Targeted Ocular Drug Delivery with Pharmacokinetic/Pharmacodynamic Considerations

被引:34
|
作者
Shen, Jie [1 ]
Lu, Guang Wei [2 ]
Hughes, Patrick [3 ]
机构
[1] Allergan Plc, Clin Pharmacol Nonclin & Translat Sci, 2525 Dupont Dr, Irvine, CA 92612 USA
[2] TWi Pharmaceut Inc, Ophthalm Prod Dev, Taipei, Taiwan
[3] Glaukos Corp, Appl Res, San Clemente, CA USA
关键词
formulation; ocular; pharmacokinetic; pharmacodynamic; sustained release; targeted delivery; EPISCLERAL CYCLOSPORINE IMPLANT; IN-VITRO; SUBCONJUNCTIVAL BEVACIZUMAB; SUSTAINED-RELEASE; VIVO EVALUATION; AQUEOUS-HUMOR; GLAUCOMA; PHARMACOKINETICS; LATANOPROST; ABSORPTION;
D O I
10.1007/s11095-018-2498-y
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The development of ophthalmic drug delivery systems is a long and comprehensive process including research, nonclinical, and clinical development stages. It is critical to understand the similarity and differences between animal models and patients. There are many anatomically and physiologically important parameters for targeted drug delivery into eyes. This paper reviews the constraints to various routes of ocular drug delivery and discusses the respective pharmacokinetic considerations, to lay the foundation for formulation approaches pharmaceutical scientists can use to maximize successful drug delivery for each route. The overall goal is to give both researchers and drug developers a better understanding of ocular drug delivery and offer tools to successfully develop new medicines that will fulfil unmet medical needs and improve patients' quality of life.
引用
收藏
页数:20
相关论文
共 50 条
  • [21] Considerations for Polymers Used in Ocular Drug Delivery
    Allyn, Megan M.
    Luo, Richard H.
    Hellwarth, Elle B.
    Swindle-Reilly, Katelyn E.
    FRONTIERS IN MEDICINE, 2022, 8
  • [22] Biopharmaceutical considerations in topical ocular drug delivery
    Davies, NM
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2000, 27 (07) : 558 - 562
  • [23] Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs
    Matera, Maria Gabriella
    Calzetta, Luigino
    Ora, Josuel
    Rogliani, Paola
    Cazzola, Mario
    EXPERT OPINION ON DRUG DELIVERY, 2021, 18 (07) : 891 - 906
  • [24] DRUG-INTERACTIONS IN HYPERTENSIVE PATIENTS - PHARMACOKINETIC, PHARMACODYNAMIC AND GENETIC CONSIDERATIONS
    LAM, YWF
    SHEPHERD, AMM
    CLINICAL PHARMACOKINETICS, 1990, 18 (04) : 295 - 317
  • [25] Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates
    Sapra, Puja
    Betts, Alison
    Boni, Joseph
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2013, 6 (05) : 541 - 555
  • [26] Designing Dendrimers for Drug Delivery and Imaging: Pharmacokinetic Considerations
    Wijagkanalan, Wassana
    Kawakami, Shigeru
    Hashida, Mitsuru
    PHARMACEUTICAL RESEARCH, 2011, 28 (07) : 1500 - 1519
  • [27] Designing Dendrimers for Drug Delivery and Imaging: Pharmacokinetic Considerations
    Wassana Wijagkanalan
    Shigeru Kawakami
    Mitsuru Hashida
    Pharmaceutical Research, 2011, 28 : 1500 - 1519
  • [28] PHARMACOKINETIC AND PHARMACODYNAMIC BASIS FOR PEPTIDE DRUG DELIVERY SYSTEM-DESIGN
    BREIMER, DD
    JOURNAL OF CONTROLLED RELEASE, 1992, 21 (1-3) : 5 - 10
  • [29] Application of Pharmacokinetic-Pharmacodynamic Modeling in Drug Delivery: Development and Challenges
    Zou, Huixi
    Banerjee, Parikshit
    Leung, Sharon Shui Yee
    Yan, Xiaoyu
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [30] Pharmacokinetic-Pharmacodynamic Modeling of Tumor Targeted Drug Delivery Using Nano-Engineered Mesenchymal Stem Cells
    Cheng, Shen
    Nethi, Susheel Kumar
    Al-Kofahi, Mahmoud
    Prabha, Swayam
    PHARMACEUTICS, 2021, 13 (01) : 1 - 22